MedTrace Logo

MPDL3280A-imaging-IST-UMCG

NCT02453984 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-05-03

No results posted yet for this study

Summary

By performing a 89Zr-MPDL3280A-PET scan prior or during treatment with MPDL3280A, the uptake of the tracer in the primary and metastatic tumor lesions and normal organ distribution can be evaluated, as well as the use of a 89Zr-MPDL3280A-PET as a complementary tool for patient selection and MPDL3280A- target saturation during treatment.

Conditions

  • Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression

Interventions

OTHER

89Zr-MPDL-3280A-PET scans

89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Elisabeth de Vries, Professor · UMCG

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-24
Primary Completion
2020-11-23
Completion
2024-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453984 on ClinicalTrials.gov